Aspirin plus clopidogrel versus cilostazol -based triple antiplatelet therapy in patients with ischemic heart disease undergoing PCI: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Introduction

Cilostazol has been widely used to prevent peripheral vascular events after PCI. However, guidelines in cilostazol-based triple antiplatelet therapy for patients with ischemic heart disease undergoing PCI remain unclear. The purpose of this study was to assess the efficacy and safety of DAPT (aspirin and clopidogrel) compared to cilostazol -based TAPT (aspirin, clopidogrel and cilostazol).

Methods

We conducted a comprehensive search of the Medline, Embase, Scopus, Cochrane, and Web of Science databases until November 2024 to identify RCTs comparing DAPT with cilostazol -based TAPT in patients with ischemic heart disease undergoing PCI. Pooled risk ratios (RRs) with 95% CIs were calculated.

Results

Eight RCTs (5,299 patients) were included in this systemat

SUBMITTER: Odat RM 

PROVIDER: S-EPMC11841151 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature